Oppenheimer upgrades Incyte to Outperform from Perform, raises price target to $144 from $120

Incyte secured an interim injunction in India against Melody Healthcare regarding its ruxolitinib patent, just 11 weeks before the patent's expiration. The Delhi High Court ruled in favor of interim protection due to the patent's remaining validity and lack of competing commercial launch. According to the court, this ruling highlights the availability of interim protection against threatened infringement before a rival's commercial launch.

Incyte (INCY) will present new data on its hematology portfolio at ASH 2026, including updates on INCA033989 for myelofibrosis and essential thrombocythemia, and latarcibart for von Willebrand disease. Over 30 abstracts will be shared, with an investor event scheduled for December 12, 2026.

A phase 3 study found that ruxolitinib cream was well tolerated and maintained disease control in children aged 2-11 with mild to moderate atopic dermatitis (AD) over 44 weeks. The study, funded by Incyte Corporation, showed 79.5% of children on 0.75% strength and 72.3% on 1.5% had clear or almost clear skin at week 52. Common side effects included upper respiratory tract infection and neutropenia. The authors suggest ruxolitinib cream as a potential corticosteroid-free treatment option for AD.

Incyte (INCY) reported Q3 revenue of $1.56B, up 14% YoY, with net sales also rising 14% to $1.32B. All products grew, led by Jakafi and OPZELURA. The company raised full-year sales guidance to $5.21B-$5.3B. Management highlighted a larger late-stage pipeline but noted risks including higher expenses and pricing pressure on Jakafi.

Incyte (INCY) and Genmab (GMAB) will jointly fund a Phase 1/2 trial combining Incyte's KRAS G12D inhibitor (INCB161734) and Genmab's bispecific antibody (petosemtamab) with chemotherapy for metastatic colorectal cancer with KRAS G12D mutation. The trial aims to evaluate the combination's safety and efficacy, targeting a subtype with limited treatment options.

Oppenheimer upgraded Incyte to Outperform, citing growth prospects beyond Jakafi's 2029 exclusivity loss. The firm set a $144 price target, 23% above Incyte's Oct. 29 closing price.